ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimabs Unique Mechanism of Action in the Treatment of Atopic Dermatitis
ASLNDelisted Stock | USD 0.60 0.03 4.76% |
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Aslan |
SAN MATEO, Calif. and SINGAPORE, June 23, 2023 ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the publication of data from the Phase 1a single ascending dose study of eblasakimab, a monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, in Clinical Immunology, a bimonthly peer-reviewed journal, supporting
Read at finance.yahoo.com
Aslan Pharmaceuticals Fundamental Analysis
We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Aslan Pharmaceuticals is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Aslan Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aslan Pharmaceuticals Related Equities
LYRA | Lyra Therapeutics | 10.53 | ||||
ANEB | Anebulo Pharmaceuticals | 7.64 | ||||
TIL | Instil Bio | 6.01 | ||||
CTMX | CytomX Therapeutics | 4.88 | ||||
ERAS | Erasca | 1.95 | ||||
CGEM | Cullinan Oncology | 1.25 | ||||
AGIO | Agios Pharm | 0.97 | ||||
GPCR | Structure Therapeutics | 0.90 | ||||
IVA | Inventiva | 0.77 | ||||
ASMB | Assembly Biosciences | 0.55 | ||||
ANTX | AN2 Therapeutics | 0.67 | ||||
ACHL | Achilles Therapeutics | 0.93 | ||||
MLYS | Mineralys Therapeutics, | 2.49 | ||||
AVTE | Aerovate Therapeutics | 2.67 | ||||
IOBT | IO Biotech | 4.44 | ||||
ADAG | Adagene | 6.01 | ||||
GLUE | Monte Rosa | 6.29 | ||||
CMPX | Compass Therapeutics | 6.79 | ||||
NAMS | NewAmsterdam Pharma | 8.56 | ||||
ACRV | Acrivon Therapeutics, | 9.66 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Transaction History View history of all your transactions and understand their impact on performance | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |